Prognostic immunohistologic markers in human tumors: why are so few used in clinical practice? (Q79950076)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855595%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

Prognostic immunohistologic markers in human tumors: why are so few used in clinical practice? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855595%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Yasodha Natkunam

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855595%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

David Y Mason

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855595%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

19 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855595%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

published in

Laboratory Investigation

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855595%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

86

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855595%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855595%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

742-747

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16855595%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/labinvest.3700447

27 December 2019

exact match

0 references

cites work

A pooled analysis of magnetic fields and childhood leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Childhood cancer in relation to distance from high voltage power lines in England and Wales: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Histologic and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Building an outcome predictor model for diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

A survey of 246 suggested coronary risk factors

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Molecular portraits of breast cancer: tumour subtypes as distinct disease entities

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Determination of stromal signatures in breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Paradoxical roles of the immune system during cancer development

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700447

7 January 2021